Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the recipient of a significant decline in short interest in the month of November. As of November 29th, there was short interest totalling 2,640,000 shares, a decline of 11.7% from the November 14th total of 2,990,000 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average trading volume of 1,140,000 shares, the short-interest ratio is presently 2.3 days.
Several equities research analysts have recently weighed in on the company. HC Wainwright set a $3.00 price objective on Protalix Biotherapeutics and gave the company a “buy” rating in a research note on Friday, October 18th. Zacks Investment Research upgraded Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th.
An institutional investor recently raised its position in Protalix Biotherapeutics stock. Wedbush Securities Inc. grew its stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 70.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 145,000 shares of the company’s stock after purchasing an additional 60,000 shares during the period. Wedbush Securities Inc. owned approximately 0.10% of Protalix Biotherapeutics worth $30,000 as of its most recent filing with the Securities and Exchange Commission.
PLX stock opened at $0.28 on Friday. Protalix Biotherapeutics has a 1-year low of $0.17 and a 1-year high of $0.60.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company had revenue of $14.25 million during the quarter, compared to the consensus estimate of $11.60 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share.
Protalix Biotherapeutics Company Profile
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Featured Story: What is a put option?
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.